AI-Powered Medical Devices: Funding & Acquisition Landscape in 2026
A data-driven analysis of the AI medical device investment boom — covering the Medtronic/CathWorks deal, Zimmer Biomet/Monogram acquisition, HistoSonics' $2.25B valuation, record FDA AI clearances, and how AI now drives 55% of all health tech funding in 2025-2026.
AI Is No Longer a Niche in Medtech — It Is the Market
The era of AI as a "nice-to-have" bolt-on for medical device companies is over. In 2025-2026, artificial intelligence has become the single most important driver of medtech deal flow, venture funding, and strategic M&A. The numbers are unambiguous:
- AI companies captured 55% of all health tech venture funding in 2025, up from 37% in 2024, 33% in 2023, and just 29% in 2022, according to Bessemer Venture Partners' State of Health AI 2026 report
- 50% of all digital health deals in 2025 went to AI-enabled companies, matching the broader VC market, per Rock Health's year-end funding analysis
- 295 AI/ML medical devices received FDA authorization in 2025 alone — a new annual record — bringing the cumulative total to 1,451 through year-end 2025
- $92.8 billion in medtech M&A was completed through November 2025, the highest total in over a decade, with AI themes appearing in more than 20% of all megadeals ($5B+), per PwC
This article tracks the most significant AI medical device acquisitions and funding events in 2025-2026, analyzes the strategic forces driving this capital allocation, and maps where AI-enabled medtech investment is heading next.
The Landmark Acquisitions: Strategic Acquirers Buying AI Capabilities
Medtronic / CathWorks — $585M (February 2026)
Medtronic's acquisition of CathWorks for up to $585 million (with potential additional earn-out payments) is the clearest signal that major device OEMs now view AI software as a core strategic asset, not an accessory.
What Medtronic bought: CathWorks developed the FFRangio System, an AI-powered angiography-derived fractional flow reserve (FFR) platform that eliminates the need for invasive pressure wires and drug stimulation during coronary artery disease (CAD) assessment. Using artificial intelligence and computational science, the system delivers real-time FFR values for the entire coronary tree from routine angiograms.
Background: The deal stems from a 2022 strategic partnership in which Medtronic co-promoted the FFRangio System in the U.S., Europe, and Japan. After three years of commercial validation, Medtronic exercised its option to acquire.
Strategic rationale:
- Transforms the cath lab: As Medtronic SVP Jason Weidman stated, "This acquisition allows Medtronic to transform the cath lab with a technology that provides real-time data, informs individualized treatment approaches, and drives new standards of care."
- Disrupts a $2B+ FFR market: Wire-based FFR is notoriously underutilized due to its invasive nature. AI-derived FFR addresses this adoption gap.
- Strengthens Medtronic's cardiovascular portfolio: With pacemakers, PFA, and now AI diagnostics, Medtronic is building an end-to-end cardiovascular technology stack.
Financial impact: The deal is expected to be immaterial to Medtronic's FY2027 adjusted EPS and neutral to accretive thereafter. CathWorks' FFRangio has been endorsed by the Society for Cardiovascular Angiography & Interventions (SCAI) as of February 2026.
Zimmer Biomet / Monogram Technologies — $177M (July 2025)
Zimmer Biomet's acquisition of Monogram Technologies for approximately $177 million upfront (plus up to $12.37 per share in milestone-based contingent value rights through 2030) exemplifies how AI is reshaping surgical robotics M&A.
What Zimmer Biomet bought: Monogram developed the mBOS system, a CT-based, semi-autonomous, AI-navigated robotic platform for total knee arthroplasty (TKA). The system received FDA 510(k) clearance in March 2025 and Monogram began clinical trials for its fully autonomous version in July 2025.
Strategic rationale:
- Path to full autonomy: Zimmer Biomet CEO Ivan Tornos stated the acquisition creates "a clear pathway to become the first and only company in orthopedics to offer a fully autonomous surgical robot."
- Expands ROSA platform: Monogram's CT-based, AI-navigated technology complements Zimmer Biomet's existing ROSA imageless robotics platform, giving surgeons the broadest choice of robotic approaches.
- Competitive positioning: The deal strengthens Zimmer Biomet's position against Stryker (Mako), Smith+Nephew, and Johnson & Johnson in the surgical robotics arms race.
Timeline: The deal closed in October 2025. Commercialization with Zimmer Biomet implants is expected in early 2027.
HistoSonics — $2.25B Majority Stake Acquisition + $250M Growth Round (2025)
While not purely an "AI" deal, HistoSonics represents the convergence of advanced computational technology and therapeutic innovation that is attracting the largest checks in medtech.
What happened:
- August 2025: A consortium including K5 Global, Bezos Expeditions, and Wellington Management acquired a majority stake in HistoSonics, valuing the company at $2.25 billion
- October 2025: HistoSonics raised an additional $250 million in an oversubscribed Series D growth round, with Thiel Bio and Founders Fund participating
What HistoSonics built: The Edison Histotripsy System uses focused ultrasound to non-invasively destroy liver tumors at a sub-cellular level — no needles, no incisions, no thermal damage to surrounding tissue. The system received FDA De Novo clearance in October 2023 and has treated over 2,000 patients at more than 50 active centers worldwide.
Why it matters for AI-enabled medtech: HistoSonics' approach relies on advanced computational algorithms for real-time beam focusing and image guidance. The company's success — projecting $100 million in 2025 revenue and $200 million in 2026 — demonstrates that investors are willing to pay premium valuations for technology platforms that combine computational sophistication with proven clinical outcomes.
Insurance coverage momentum: Elevance Health (formerly Anthem) issued a positive coverage policy in October 2025 across 14 states, and Highmark Blue Cross Blue Shield extended coverage to 7 million members. Medicare pays approximately $17,500 per histotripsy procedure.
The Venture Capital Landscape: AI Commands a Premium
Headline Numbers
The venture capital market for AI-enabled health tech reached a scale that dwarfs every prior cycle:
| Metric | 2024 | 2025 | Change |
|---|---|---|---|
| Total health tech VC deals | ~500 | 527 | +5% |
| Total capital deployed | ~$10B | ~$14B | +40% |
| Average deal size | $20.7M | $29.3M | +42% |
| AI share of total funding | 37% | 55% | +18pp |
| Mega-rounds ($100M+) | N/A | 11 (9 AI-enabled) | — |
Source: Bessemer Venture Partners, State of Health AI 2026
The AI Valuation Premium
AI-enabled companies are commanding substantially higher valuations at every stage. Rock Health found that AI-enabled digital health startups captured 54% of total 2025 funding and earned a 19% premium on average deal size compared to non-AI companies. The premium was most pronounced at Series C, where AI startups commanded a 61% premium over non-AI peers.
Series D+ valuations increased 63% year-over-year from 2024 to 2025, driven almost entirely by AI-enabled companies.
Notable Mega-Rounds (2025-2026)
Several AI-powered health tech companies raised rounds that would have been unthinkable two years ago:
| Company | Round | Amount | Valuation | Focus |
|---|---|---|---|---|
| Abridge | Series E | $300M | $5B | AI ambient clinical documentation |
| Ambience Healthcare | Series C | $243M | $1.04B | AI-powered clinical documentation |
| Function Health | Series C | $300M | $2.2B | AI-driven health testing platform |
| HistoSonics | Growth | $250M | $2.25B | Computational histotripsy |
| OpenEvidence | Series B (rumored) | $250M | $11.75B | AI clinical decision support |
Sources: Bessemer Venture Partners, Fierce Biotech, company press releases
Radiology AI Funding Rebounds
After a multi-year decline from pandemic-era peaks, VC funding for medical imaging AI companies bounced back in 2025, according to Signify Research. Investors became more selective, focusing on companies with demonstrated clinical workflow integration and proven ROI.
Notable recent rounds include:
- a2z Radiology AI — $4.5M seed round (December 2025). The Boston-based startup, led by Stanford researchers Pranav and Samir Rajpurkar, is building generalist AI systems for comprehensive medical imaging interpretation. Its first FDA-cleared product reduced radiologist reporting time by 18% and mental demand by 22% in prospective studies.
- Mecha Health — $4.1M seed round (2025, Y Combinator W25). Building next-generation foundation models for radiology, led by a team from University College London.
Where VCs Are Placing Bets
According to multiple industry reports (Bessemer, Rock Health, PwC), the highest-conviction AI subsectors in medtech for 2026 are:
- Clinical workflow automation — ambient documentation, AI scribes (92% of provider health systems deploying or piloting as of March 2025)
- AI-powered diagnostics — radiology, pathology, cardiology AI software
- Surgical intelligence — AI navigation, autonomous robotics, procedure planning
- Revenue cycle management (RCM) — AI-first architectures replacing offshore labor models
- Data infrastructure — healthcare-specific data platforms serving AI model developers
FDA AI/ML Device Authorizations: A Record-Breaking Trajectory
The Numbers
The FDA's AI/ML-Enabled Device tracker tells a clear story of exponential adoption:
| Year | New AI/ML Authorizations | Cumulative Total |
|---|---|---|
| 2020 | ~70 | ~200 |
| 2021 | ~115 | ~350 |
| 2022 | ~160 | ~520 |
| 2023 | ~170 | ~690 |
| 2024 | ~220 | ~950 |
| 2025 | 295 | ~1,250 |
| Through March 2026 | ~200+ | 1,451 |
Source: FDA AI/ML-Enabled Medical Device Database; Innolitics 2025 Year in Review; Bertalan Mesko analysis
Key Patterns
Radiology dominates but diversification is underway. Radiology imaging accounts for approximately 76% of all FDA-authorized AI devices. However, cardiovascular and neurology applications are the fastest-growing categories, and new specialties (gastroenterology, ophthalmology, dermatology) are emerging.
No generative AI yet. As of March 2026, no device has been authorized that uses generative AI or is powered by large language models (LLMs), according to Dr. Bertalan Mesko's analysis of the FDA database. Every cleared device uses "classical" ML — convolutional neural networks, random forests, gradient boosting, and other supervised learning approaches.
510(k) is the dominant pathway. The vast majority of AI devices reach market through the 510(k) pathway, using predicate devices to establish substantial equivalence. The FDA's Predetermined Change Control Plan (PCCP) guidance is enabling more manufacturers to build algorithm updates into their initial submissions, reducing the regulatory burden of iterative improvement.
PCCP adoption is growing. More companies are using PCCPs to pre-specify how their AI algorithms will be updated post-market, which the FDA has encouraged through finalized guidance.
The Strategic Logic: Why Every Major OEM Is Buying AI
From Bolt-On to Core Strategy
PwC's 2026 M&A outlook captures the shift precisely: "Investors will increasingly treat AI as a core driver of margin expansion and top-line growth — not a bolt-on enhancement — shifting valuation premiums toward platforms with proven operations leveraging real data."
The implications for medtech M&A are profound:
AI is a valuation multiplier. Companies that embed AI into their device platforms command higher acquisition multiples than pure hardware companies. The Medtronic/CathWorks deal structure — with earn-outs tied to post-acquisition performance — reflects acquirers' willingness to pay premium prices for AI capabilities with proven clinical utility.
Data moats matter. Acquirers are not just buying algorithms; they are buying proprietary clinical datasets that improve over time. CathWorks' FFRangio system, for example, becomes more valuable with every procedure because the underlying data set grows.
Speed of clinical adoption. AI-powered ambient clinical documentation scribes achieved near-universal adoption (92% of health systems deploying, implementing, or piloting) in just 2-3 years. EHR systems took 15 years. This adoption velocity makes AI targets exceptionally attractive to acquirers.
The "Buy vs. Build" Calculus
For large medtech companies, the acquisition math is increasingly clear:
- Building AI in-house requires recruiting scarce ML engineering talent, acquiring and curating proprietary training data, navigating FDA regulatory pathways, and achieving commercial traction — a process that takes 3-5+ years and carries high execution risk
- Acquiring AI companies with FDA-cleared products, clinical evidence, and commercial traction provides immediate capability at a known cost
This calculus is driving a wave of strategic acquisitions (Medtronic/CathWorks, Zimmer Biomet/Monogram) and is expected to accelerate through 2026 as more AI startups reach commercial maturity.
Corporate Venture Arms Are Back in Force
The resurgence of corporate venture capital in AI medtech is a notable 2025-2026 trend. Medtronic Ventures, JJDC (Johnson & Johnson), and Philips Ventures are all deploying capital into early-stage AI companies, using these investments as option-value bets that can convert to full acquisitions (as Medtronic's CathWorks partnership did).
Meanwhile, strategic OEM partnerships with AI companies are proliferating:
- Philips and Edwards Lifesciences — co-developing "DeviceGuide AI" to bring AI into cardiac repair procedures
- GE Healthcare and Volta Medical — integrating AI with electrophysiology recording systems
- Stryker and Siemens Healthineers — co-developing a robotic system for neurovascular interventions
- Abbott — partnering with Tandem Diabetes Care, Beta Bionics, Sequel Med Tech, and Ypsomed to integrate AI-enabled insulin delivery with monitoring sensors
J.P. Morgan reported in December 2025 that AI-focused deals now make up 75% of health tech funding — a remarkable concentration that underscores how central AI has become to the medtech investment thesis.
Emerging Companies to Watch
Beyond the headline deals, several AI-enabled medtech companies are attracting significant funding and strategic attention:
- Petal Surgical — emerged from stealth in 2025 with $20M in funding for acoustic liquefaction technology, representing a new category of non-mechanical, AI-guided tissue destruction
- Beacon Biosignals — raised $86M Series B for AI-powered wearable EEG devices that generate objective biomarkers of brain function during sleep
- Caresyntax — AI-powered surgical intelligence platform attracting investment as operating room data analytics grows in strategic importance
- Viz.ai — AI-powered stroke detection and care coordination platform, named among the Medical Futurist's top 100 digital health companies for 2026
- Qure.ai — expanded its FDA-authorized chest X-ray portfolio to 26 total imaging indications, demonstrating the "land and expand" strategy that drives AI medtech valuations
Market Size and Growth Projections
The global AI in healthcare market is one of the fastest-growing segments in all of technology:
| Metric | Value |
|---|---|
| 2025 market size | $39.34 billion |
| 2026 projected | $56.01 billion |
| 2034 projected | $1,033.27 billion |
| CAGR (2026-2034) | 43.96% |
Source: Fortune Business Insights
Within this broader market, AI-enabled medical devices represent a rapidly growing subsegment. Analysts project the AI-enabled medical device market specifically could grow from roughly $14 billion in 2024 to over $250 billion by 2033.
Global Health Tech M&A Context
The M&A environment in 2025 set records across multiple dimensions:
- Global health tech M&A reached 400 deals in 2025, up from 350 in 2024 (Bessemer)
- Digital health M&A surged to 195 deals, up 61% from 2024, with the highest proportion of digital health acquirers (66%) since Rock Health began tracking in 2013
- PE health tech spending increased nearly 600% compared to 2024 (Pitchbook, per Rock Health)
- Global health industries M&A deal values rose 46% YoY in 2025, driven by 11 megadeals over $5B (PwC)
The Regulatory Landscape: FDA, EU AI Act, and International Harmonization
FDA's Evolving AI Framework
The FDA's regulatory approach to AI medical devices is maturing along several parallel tracks:
Total Product Lifecycle (TPLC) guidance — The FDA is finalizing guidance that treats AI devices as continuously evolving products rather than static clearances. This is especially important for algorithms that learn and improve from real-world data.
Predetermined Change Control Plans (PCCP) — Finalized guidance allows manufacturers to pre-specify acceptable algorithm modifications, reducing the need for new submissions with each update.
Foundation model tracking — The FDA has announced plans to update its AI-enabled devices database to tag devices that use foundation AI models (including LLMs), reflecting the anticipated entry of generative AI into clinical applications.
International collaboration — In January 2025, the IMDRF released final Good Machine Learning Practice (GMLP) Guiding Principles for medical device development, building on prior FDA/Health Canada/MHRA collaboration. In January 2026, the FDA and EMA published ten joint guiding principles for AI in drug development — the first transatlantic regulatory alignment on AI in pharmaceuticals, with implications for device regulation.
EU AI Act: The Coming Wave
The EU AI Act's high-risk obligations take effect in August 2026-2027, adding significant compliance requirements for AI medical devices marketed in Europe. Medical devices classified as high-risk AI systems will need to meet:
- Mandatory risk management specific to AI
- Data governance and training data requirements
- Transparency and explainability obligations
- Human oversight mechanisms
- Post-market monitoring for AI performance
This regulatory layer will sit on top of existing EU MDR/IVDR requirements, creating additional compliance costs but also potentially raising barriers to entry that favor well-funded, established companies.
What to Watch in 2026-2027
Deals on the Horizon
Deloitte's 2026 medtech trends analysis captures the competitive dynamic: "AI capability is rapidly becoming the primary competitive differentiator in medtech. The gap between leaders and laggards will likely compound over time as data and processes mature... This could also accelerate consolidation as companies that lack the resources needed to build comprehensive AI capabilities become acquisition targets."
Several dynamics suggest the AI medtech M&A cycle is far from over:
- Medtronic signaled at J.P. Morgan 2026 that it would "step up" acquisitions, with CFO Thierry Pieton indicating the company is in a position to boost M&A — CathWorks was the first move, not the last
- More "partner-to-acquire" conversions — Strategic partnerships with options to acquire (like Medtronic/CathWorks' 2022 co-promotion agreement) are increasingly common and will trigger more deals as AI products prove commercial viability
- Radiology AI consolidation — After Bayer's withdrawal from the AI platform market in 2025, the imaging AI space is ripe for consolidation among the remaining players (Aidoc, GE Healthcare, Siemens Healthineers, and specialized startups)
Key Predictions
- AI share of health tech funding will exceed 60% in 2026, continuing the trajectory from 29% (2022) to 55% (2025)
- The first generative AI / LLM-powered medical device will receive FDA authorization, likely in clinical decision support or documentation
- Surgical robotics + AI will see at least 2-3 more significant acquisitions as OEMs race to offer autonomous and AI-navigated capabilities
- EU AI Act compliance will drive a wave of consulting and platform acquisitions in H2 2026 as companies scramble to meet high-risk obligations
- Cardiology AI will emerge as the fastest-growing acquisition category, driven by PFA integration, AI-derived FFR adoption, and the success of the Medtronic/CathWorks model
Implications for Medical Device Professionals
For Startups and Innovators
- AI is table stakes. Investors are not funding "medical devices that happen to use AI" — they are funding "AI companies that happen to work in healthcare." The framing matters for fundraising positioning.
- Clinical evidence is the differentiator. With 1,451 AI devices now authorized, clearance alone is not enough. Companies with prospective clinical data showing measurable workflow or outcome improvements command premium valuations and attract strategic acquirers.
- Partner early. The Medtronic/CathWorks playbook — co-promotion partnership followed by acquisition — is becoming the template. Strategic partnerships with large OEMs de-risk the path to exit.
For Strategic Acquirers
- Move now. The window to acquire best-in-class AI platforms at reasonable multiples is closing. Series D+ valuations are up 63% YoY and competition for proven AI assets is intensifying.
- Integrate, don't isolate. Successful AI acquisitions embed the technology across the acquirer's existing product portfolio (as Medtronic is doing with CathWorks across its cardiovascular business), rather than operating AI as a standalone unit.
For Regulatory Professionals
- Dual compliance is coming. AI medical devices marketed in both the U.S. and EU will need to satisfy both FDA's TPLC framework and the EU AI Act's high-risk requirements. Building compliance infrastructure now will pay dividends when the EU AI Act obligations take full effect in 2026-2027.
- PCCP expertise is in demand. As more companies adopt Predetermined Change Control Plans for their AI devices, regulatory professionals who understand this pathway will be increasingly valuable.
Conclusion
The convergence of record FDA clearances, surging venture capital, and transformative strategic acquisitions has made AI the defining investment thesis in medical devices for 2025-2026. Companies that are embedding AI into their core product strategies — whether through internal development, strategic partnerships, or acquisitions — are positioning themselves for the next decade of medtech growth. Those that treat AI as peripheral risk being left behind in a market that has decisively shifted.
The data is clear: AI is not coming to medtech. It is already here, it is funded at scale, and it is reshaping how every major device company thinks about its future.